CommonKind VC Research
Investment Thesis
CommonKind (stylized "commonkind vc") is a pre-seed and seed stage venture fund that backs founders who expand the common good for humankind, starting with healthcare. The firm invests in technologies that harness data to do three things: drive scalable improvements in the efficiency of care delivery, enable fundamental advances in the quality and effectiveness of care, and push the frontier and expand the toolkit that defines what care can be. Its website describes the fund as investing across healthcare and life sciences, favoring companies that are AI native, workflow embedded and vertically integrated.
Stage Focus
CommonKind invests at pre-seed and seed. It is a new fund, founded in 2025, and participated in a later-stage round alongside other healthcare investors in November 2026.
Check Size
CommonKind does not publish its check size. Third-party fund databases estimate an initial check of roughly $150K to $750K, which is an estimate and not a figure the firm states.
Lead Tendency
CommonKind's only publicly reported investment, Akara, was a round led by Locke Health, with CommonKind participating. The firm has not stated whether it leads rounds.
Recent Activity
In November 2026, Akara, a Dublin-based hospital operations technology company and Trinity College Dublin spinout, announced $5.5 million in venture funding, bringing its total raised to $12.3 million. The round was led by Locke Health, with participation from VTC Ventures, the EIC Fund, CommonKind and NovaVector Holdings, alongside existing investors ACT, Atlantic Bridge and Enterprise Ireland. Akara combines privacy-preserving sensing, AI and robotics to reduce hospital administrative work, coordinate services and treat more patients.
Regulatory filings show an investment vehicle, Commonkind 1, LP, with a 2025 vintage and a reported $15 million offered and sold. The firm has not published fund size on its own site.
Portfolio Highlights
The only investment CommonKind has disclosed publicly is Akara (healthcare operations automation, Ireland). The firm does not publish a portfolio page.
Team
- Bryan Yoo, General Partner: Founder of the fund and former co-founder and CEO of Nuanced Health, a preclinical R&D company. He holds a PhD in Cellular and Molecular Neurobiology and an undergraduate degree from Stanford University. Based in California.
CommonKind lists no other team members publicly.
Decision Process
The fund appears to be run by a single general partner, so decisions are most likely made by Bryan Yoo alone. The firm has not described its process.
Founder Preferences
CommonKind backs founders building healthcare and life sciences technology that uses data to make care delivery more efficient, improve outcomes or expand what care can do. It favors companies whose products are AI native, embedded in clinical or operational workflows, and vertically integrated. Founders with healthcare or life sciences operating backgrounds fit the profile of the GP himself.
Geographic Focus
The fund is based in Los Angeles, California. It describes no geographic limit, and its one reported investment is in Ireland, so it invests beyond North America.
CommonKind does not publish the stage or date of most of its activity, and its website carries only a short description and a link to the GP's LinkedIn profile.